Abstract: The present invention discloses a method of real-time quantification of a target nucleic acid in a sample by constructing a reference table of copy number vs. designated parameter from reference samples which sharing the same nucleic acid sequences with the target nucleic acid. The method includes (a) constructing a reference table of copy number vs. designated parameter from reference samples; (b) amplifying the target nucleic acid; (c) monitoring and detecting the amplification of the target nucleic acid in real-time; (d) analyzing the detected signals to get the designated parameter of the target nucleic acid; and (e) looking up and interpolating to the reference table to get the copy number of the target nucleic acid.

Abstract: The invention relates to methods for indirectly determining clinical laboratory reference intervals. In one aspect, a reference interval is determined using all measurements for a given analyte stored in a large existing database. In other aspects, a characteristic of a subject is used to select a reference population for inclusion in reference interval calculations. In other aspects, the invention provides methods for changing treatment plan, diagnosis, or prognosis for an individual subject based on differences between the new reference interval and a previously utilized reference interval. In other aspects, the invention provides systems and computer readable media for indirectly determining reference intervals.

Abstract: A method for verifying an ILS signal for DNA processing includes obtaining the ILS signal, determining acquisition times between peaks of the ILS signal, obtaining acquisition times between peaks in reference ILS information for the ILS signal, and verifying the ILS signal based on the ILS acquisition times and the reference ILS acquisitions times. An ILS signal processor includes a false peak remover that removes any false peaks in an ILS signal and a signal verifier that verifies the ILS signal includes only true peaks based on reference ILS information for the ILS signal.

Abstract: Techniques for generating therapy biomarker scores and visualizing same. The techniques include determining, using a patient's sequence data and distributions of biomarker values across one or more reference populations, a first set of normalized scores for a first set of biomarkers associated with a first therapy, and a second set of normalized scores for a second set of biomarkers associated with a second therapy, generating a graphical user interface (GUI) including a first portion associated with the first therapy and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the first set of normalized scores; and a second portion associated with a second therapy and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the second set of normalized scores; and displaying the generated GUI.

Abstract: A method is described for characterising a sample comprising at least DNA and/or RNA. The method comprises obtaining a UV-VIS spectroscopic measurement of the sample comprising at least DNA and/or RNA, deriving an absorption parameter based on the UV-VIS spectroscopic measurement, and determining a DNA and/or RNA quantification present in the sample. Determining a DNA and/or RNA quantification thereby comprises taking into account a buffer and/or salt effect on the UV-VIS spectroscopic measurement irrespective of the actual buffer and salt content of the sample, based on said derived absorption parameter and reference spectral data including spectral information for buffer and/or salt effects.

Abstract: A map generator can be programmed to generate a multi-parameter graphical map by encoding at least two different physiological parameters for a geometric surface, corresponding to tissue of a patient, using different color components of a multi-dimensional color model such that each of the different physiological parameters is encoded by at least one of the different color components.

Abstract: The present methods for predicting coreceptor tropism may include obtaining the amino acid and/or nucleic acid sequence of at least a portion of the envelope or envelope coding region from a biological sample obtained from a subject; analyzing the amino acid sequence, nucleic acid sequence, or both of the portion of the envelope or envelope coding region using a case based reasoning analysis; and determining the coreceptor tropism. Also described are systems and computer readable media for utilizing the systems or performing the methods.

Abstract: Inaccurate agronomic data may be identified and corrected by obtaining agronomic data indicating areas of sub-regions of a farmable region and value for the sub-regions, wherein the value for each sub-region includes an aggregate value of an agronomic parameter for the sub-region and/or a ratio of the aggregate value to the area of the sub-region; identifying a part of a first sub-region that overlaps a part of a second sub-region; determining whether the second sub-region is associated with a first pass or a second pass by a sensor through the overlapping parts; and if the second sub-region is associated with the second pass, determining an adjusted value for the second sub-region based on the value for the first sub-region, the value for the second sub-region, the area of the first sub-region, the area of the second sub-region, and/or an area of the overlapping parts.

Abstract: Provided herein are methods, processes, systems, machines and apparatuses for non-invasive assessment of chromosome alterations.

Abstract: The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals having a colorectal neoplasm by detecting the presence of exfoliated epithelial markers (e.g., human DNA, tumor assoicated gene alterations, tumor associated proteins) and blood markers (e.g., homoglobin, serum proteins) in a stool sample obtained from the mammal.

Abstract: Methods of identifying altered leukocyte profiles are disclosed. In one embodiment, counts or relative percentages of leukocyte cell types are received and constitute input data points. Combinations of input data points are generated. Pairs of input data points and combinations are generated. Secondary data values are generated from the pairs. Three-dimensional plots are then constructed and selected as useful for identifying an altered leukocyte profile through pattern recognition of perpendicular data inflection, data bifurcation, non-overlapping data clusters, or combinations thereof. Such a strategy results in partially or totally non-overlapping data subsets, which are then interpreted.

Abstract: A phenotypic profiling method for drug/dose physiological response of living bodies utilizes feature recognition to segment the information in time-frequency tissue-response spectrograms to construct N-dimensional feature vectors. The feature vectors are used to generate a correlation matrix among a large number of different stimuli in the form of drugs, doses and conditions. Multi-dimensional scaling is applied to the correlation matrix to form a two-dimensional map of response relationships that retains rank distances from the higher-dimensionality feature matrix. The two-dimensional phenotypic profile space displays compact regions indicative of particular physiological responses, such as regions of enhanced active transport, membrane undulations and blebbing.

Abstract: The invention generally relates to methods and systems for manipulating droplet size. In certain aspects, the invention provides methods for manipulating droplet size that include forming droplets of aqueous fluid surrounded by an immiscible carrier fluid, and manipulating droplet size during the forming step by adjusting pressure exerted on the aqueous fluid or the carrier fluid.

Abstract: A computer-implemented method of characterizing metal content and chemical composition of crude oil, including determining at least one respective organometallic class and subclass derived from physical and chemical property data for each organometallic class and crude oil physical and chemical property data and at least one segment type and segment number range of the segment type bound to each organometallic subclass. The method determines a relative ratio of each organometallic class and subclass that forms a chemical composition representative of the given crude oil, such that the determined relative ratio and the determined respective organometallic class and subclass, segment type, and segment number range form a characterization of the metal content and the chemical composition of the given crude oil, resulting in a display, as output to an end-user, of the formed characterization of the metal content and the chemical composition of the given crude oil.

Abstract: CNA biomarkers can include nucleic acid sequences that are present in circulating nucleic acids obtained from circulatory systems of a population known to have cancer, but that are rarely present, if at all, in circulating nucleic acids obtained from circulatory systems of a control population. Information is received describing one or more sequences obtained from circulating nucleic acids in a population known to have cancer. Information is also received describing one or more sequences obtained from circulating nucleic acids in a control population. A cluster analysis within a predetermined portion of a genome uses the one or more sequences in the circulating nucleic acids obtained from the population known to have cancer and the one or more sequences in the circulating nucleic acids obtained from the control population. Information is generated identifying one or more biomarkers for the cancer based on a cluster search within results of the cluster analysis.

Abstract: Provided is an information processing apparatus, including a testing section performing statistical testing on simple staining data obtained by performing fluorescence measurement on a particle subjected to simple staining with a staining material having a prescribed fluorescence characteristic and unstaining data obtained by performing fluorescence measurement on an unstained particle for comparison for a frequency band, a masking processing section setting, in a case where there is no significant difference between the simple staining data and the unstaining data for the frequency band, the simple staining data to 0 or a prescribed value, and an estimation section estimating, in a manner that double staining data obtained by performing fluorescence measurement on a particle stained with a plurality of staining materials is represented by a linear combination of base vectors representing a distribution of the simple staining data corresponding to each staining material, a combination coefficient of the linea

Abstract: Activated clotting time (ACT) tests detect blood clotting time based on the viscosity changes of a test sample, using a ferromagnetic washer lifted to the top of a test chamber and then dropped from the top via gravity; a drop time greater than a preset threshold value indicates clotting of the test sample. Blood samples which have high levels of heparin usually produce very weak clots that may easily be destroyed by the lifting movement of the washer. But if the clot threshold is set low to detect the weak clots, false detections occur during early testing cycles when activators are not fully suspended during the mixing cycle. Improved algorithms for lifting the washer and adjusting over time enable accurate detection of weak clots.

Abstract: A method and system for non-invasive assessment of coronary artery stenosis is disclosed. Patient-specific anatomical measurements of the coronary arteries are extracted from medical image data of a patient acquired during rest state. Patient-specific rest state boundary conditions of a model of coronary circulation representing the coronary arteries are calculated based on the patient-specific anatomical measurements and non-invasive clinical measurements of the patient at rest. Patient-specific rest state boundary conditions of the model of coronary circulation representing the coronary arteries are calculated based on the patient-specific anatomical measurements and non-invasive clinical measurements of the patient at rest. Hyperemic blood flow and pressure across at least one stenosis region of the coronary arteries are simulated using the model of coronary circulation and the patient-specific hyperemic boundary conditions.

Abstract: A method and system for non-invasive assessment of coronary artery stenosis is disclosed. Patient-specific anatomical measurements of the coronary arteries are extracted from medical image data of a patient acquired during rest state. Patient-specific rest state boundary conditions of a model of coronary circulation representing the coronary arteries are calculated based on the patient-specific anatomical measurements and non-invasive clinical measurements of the patient at rest. Patient-specific rest state boundary conditions of the model of coronary circulation representing the coronary arteries are calculated based on the patient-specific anatomical measurements and non-invasive clinical measurements of the patient at rest. Hyperemic blood flow and pressure across at least one stenosis region of the coronary arteries are simulated using the model of coronary circulation and the patient-specific hyperemic boundary conditions.

Abstract: A method and system for simulating patient-specific atrial electrophysiology is disclosed. A patient-specific anatomical atria model is generated from medical image data of a patient. A patient-specific atria electrophysiology model is generated based on the patient-specific anatomical atria model and electrophysiology measurements of the patient. One or more virtual electrophysiological therapies are performed by performing atrial electrophysiology simulations using the patient-specific atria electrophysiology model. Atrial electrophysiology simulation results resulting from the one or more virtual electrophysiological therapies are displayed.